# MLTX (Moonlake Immunotherapeutics) - SEC EDGAR Financial Statements

> Moonlake Immunotherapeutics reported $540.7M in total assets and a net loss of $273.5M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/MLTX
- Markdown: https://convexityos.com/fundamentals/MLTX.md
- SEC CIK: 0001821586
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:29 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001821586&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$276.8M | Operating profit |
| Net Income | FY 2025 | -$273.5M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$3.20 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$244.0M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $498.5M | Total debt: $101.6M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Research & Development | $202.9M | $112.8M | $31.80M | $42.05M | -- |
| Total Operating Expenses | $244.8M | $143.1M | $54.12M | $65.06M | -- |
| **Operating Income** | -$244.8M | -$143.1M | -$54.12M | -$65.06M | -$4.57M |
| **EBITDA** | -$242.2M | -$141.7M | -$53.75M | -$64.90M | -- |
| Interest Income | -- | -- | -- | -- | $28K |
| Interest Expense | $7.25M | $0 | $0 | -- | -- |
| Income Before Tax | -$229.7M | -$121.0M | -$43.98M | -$64.47M | -- |
| Income Tax Expense | $611K | $282K | $94K | $36K | -- |
| **Net Income** | -$227.3M | -$118.9M | -$36.01M | -$49.97M | -$4.54M |
| Basic EPS | -$3.53 | -$1.89 | -$0.73 | -$1.70 | -$0.31 |
| **Diluted EPS** | -$3.53 | -$1.89 | -$0.73 | -$1.70 | -$0.31 |
| Basic Shares Outstanding | 64.5M | 62.9M | 49.1M | 29.4M | 11.9M |
| Diluted Shares Outstanding | 64.5M | 62.9M | 49.1M | 29.4M | 360.0M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $68.87M | $50.22M | $54.52M | $56.01M | $60.63M | $49.76M | $36.46M | $40.36M |
| Total Operating Expenses | $79.85M | $61.66M | $70.02M | $65.22M | $71.43M | $60.70M | $47.48M | $49.58M |
| **Operating Income** | -$79.85M | -$61.66M | -$70.02M | -$65.22M | -$71.43M | -$60.70M | -$47.48M | -$49.58M |
| **EBITDA** | -$78.95M | -$60.76M | -$69.18M | -$64.47M | -$70.69M | -$59.96M | -$47.11M | -$49.22M |
| Interest Expense | $2.65M | $2.63M | $2.27M | $1.99M | $3.20M | $2.04M | $18K | $0 |
| Income Tax Expense | $631K | $90K | $622K | $248K | $115K | $95K | $153K | $41K |
| **Net Income** | -$79.55M | -$61.80M | -$69.71M | -$62.43M | -$69.73M | -$55.22M | -$39.94M | -$45.60M |
| Basic EPS | -$0.93 | -$0.84 | -$0.98 | -- | -$1.10 | -$0.87 | -$0.63 | -- |
| **Diluted EPS** | -$0.93 | -$0.84 | -$0.98 | -- | -$1.10 | -$0.87 | -$0.63 | -- |
| Basic Shares Outstanding | 85.4M | 73.9M | 71.3M | -- | 63.4M | 63.3M | 63.2M | -- |
| Diluted Shares Outstanding | 85.4M | 73.9M | 71.3M | -- | 63.4M | 63.3M | 63.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $334.5M | $180.4M | $451.2M | $39.51M | $8.04M | $1.34M |
| Short-Term Investments | $59.45M | $267.6M | $59.84M | $32.61M | $0 | -- |
| **Cash & Short-Term Investments** | $394.0M | $448.0M | $511.0M | $72.11M | $8.04M | $1.34M |
| Other Current Assets | $4.87M | -- | -- | -- | -- | -- |
| **Total Current Assets** | $421.7M | $474.3M | $514.2M | $76.51M | $9.64M | $1.62M |
| Property, Plant & Equipment, Net | $577K | $722K | $321K | $49K | $46K | -- |
| Other Non-Current Assets | $596K | $0 | -- | -- | -- | -- |
| **Total Non-Current Assets** | $2.74M | $3.64M | $12.37M | $332K | $46K | $115.0M |
| **Total Assets** | $424.4M | $477.9M | $526.5M | $76.84M | $9.68M | $116.6M |
| Short-Term Debt | -- | -- | -- | $0 | $15.00M | -- |
| **Total Current Liabilities** | $45.48M | $22.46M | $9.97M | $7.67M | $21.09M | $125K |
| Long-Term Debt | $74.10M | $0 | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $74.47M | $2.08M | $3.08M | $411K | $240K | $4.03M |
| **Total Liabilities** | $120.0M | $24.54M | $13.05M | $8.08M | $21.33M | $4.15M |
| **Total Debt (incl. Leases)** | $75.71M | $2.83M | $3.70M | $283K | $15.00M | -- |
| Common Stock | -- | -- | -- | -- | $43 | $43 |
| Retained Earnings | -$462.9M | -$235.6M | -$116.7M | -$80.65M | -$53.64M | -$2.52M |
| Accumulated Other Comp. Income | $604K | $5.00M | $2.36M | $351K | -$168K | -- |
| **Total Stockholders' Equity** | $304.5M | $446.8M | $495.7M | $48.90M | -$11.65M | -$2.52M |
| Total Equity | $304.5M | $453.4M | $513.5M | $68.77M | -$11.65M | -$2.52M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $379.7M | $477.9M | $298.5M | $334.5M | $350.7M | $306.7M | $271.6M | $180.4M |
| Short-Term Investments | $118.8M | $59.12M | $59.43M | $59.45M | $29.74M | $118.4M | $208.6M | $267.6M |
| **Cash & Short-Term Investments** | $498.5M | $537.0M | $357.9M | $394.0M | $380.5M | $425.1M | $480.1M | $448.0M |
| Other Current Assets | $8.95M | -- | -- | $4.87M | -- | -- | -- | -- |
| **Total Current Assets** | $533.3M | $570.0M | $396.6M | $421.7M | $411.2M | $455.5M | $506.3M | $474.3M |
| Property, Plant & Equipment, Net | $443K | $487K | $532K | $577K | $622K | $667K | $711K | $722K |
| Other Non-Current Assets | $5.22M | $1.34M | $1.34M | $596K | $587K | $1.70M | $1.70M | $0 |
| **Total Non-Current Assets** | $7.37M | $3.91M | $3.73M | $2.74M | $3.12M | $4.62M | $5.00M | $3.64M |
| **Total Assets** | $540.7M | $573.9M | $400.4M | $424.4M | $414.3M | $460.1M | $511.3M | $477.9M |
| **Total Current Liabilities** | $58.43M | $45.39M | $46.11M | $45.48M | $48.37M | $27.36M | $23.98M | $22.46M |
| Long-Term Debt | $100.0M | $99.51M | $99.02M | $74.10M | $73.74M | $73.38M | $73.02M | $0 |
| **Total Non-Current Liabilities** | $100.7M | $100.4M | $100.2M | $74.47M | $74.78M | $74.79M | $74.70M | $2.08M |
| **Total Liabilities** | $159.1M | $145.8M | $146.3M | $120.0M | $123.1M | $102.2M | $98.68M | $24.54M |
| **Total Debt (incl. Leases)** | $101.6M | $101.5M | $100.8M | $75.71M | $75.73M | $75.77M | $75.60M | $2.83M |
| Retained Earnings | -$674.0M | -$594.4M | -$532.6M | -$462.9M | -$400.5M | -$330.8M | -$275.5M | -$235.6M |
| Accumulated Other Comp. Income | $2.29M | $630K | $322K | $604K | $278K | $520K | $2.39M | $5.00M |
| **Total Stockholders' Equity** | $381.6M | $428.2M | $254.0M | $304.5M | $288.9M | $353.7M | $407.5M | $446.8M |
| Total Equity | $381.6M | $428.2M | $254.0M | $304.5M | $291.2M | $357.9M | $412.6M | $453.4M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Net Income | -$230.3M | -$121.2M | -$44.08M | -$64.51M | -$4.54M |
| Depreciation & Amortization | $2.62M | $1.39M | $370K | $165K | -- |
| Stock-Based Compensation | $12.90M | $7.28M | $7.11M | $9.65M | -- |
| Change in Payables | $20.56M | $7.16M | $1.58M | -$1.31M | -- |
| **Operating Cash Flow** | -$196.0M | -$116.6M | -$42.78M | -$55.89M | -$611K |
| Capital Expenditure | -$35K | -$520K | -$284K | -$16K | -- |
| **Free Cash Flow** | -$196.0M | -$117.1M | -$43.06M | -$55.91M | -- |
| Purchases of Investments | -$265.4M | -$350.3M | -$175.7M | -$42.23M | -- |
| **Investing Cash Flow** | $203.0M | -$205.6M | -$25.18M | -$32.34M | -- |
| Share Repurchases | -- | -$50 | $0 | $0 | -- |
| **Financing Cash Flow** | $146.0M | $51.31M | $479.7M | $119.7M | -$58K |
| **Net Change in Cash** | $154.1M | -$270.7M | $411.7M | $31.47M | -$669K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$79.55M | -$61.80M | -$69.71M | -$63.02M | -$70.69M | -$56.05M | -$40.56M | -$46.40M |
| Depreciation & Amortization | $905K | $896K | $845K | $751K | $745K | $742K | $378K | $364K |
| Stock-Based Compensation | $2.85M | $2.55M | $13.36M | $3.59M | $3.71M | $3.31M | $2.29M | $1.93M |
| Change in Payables | -$3.19M | -$6.34M | -$6.17M | $4.27M | $8.20M | $5.07M | $3.01M | -$1.72M |
| **Operating Cash Flow** | -$63.40M | -$55.56M | -$66.29M | -$58.79M | -$44.54M | -$54.53M | -$38.14M | -$48.47M |
| Capital Expenditure | $0 | $0 | $0 | $0 | $0 | $0 | -$35K | -$176K |
| **Free Cash Flow** | -$63.40M | -$55.56M | -$66.29M | -$58.79M | -$44.54M | -$54.53M | -$38.17M | -$48.65M |
| Purchases of Investments | -$88.29M | -$58.75M | -$59.07M | -$59.17M | $0 | -$117.7M | -$88.55M | -$146.9M |
| **Investing Cash Flow** | -$58.76M | $322K | $98K | -$29.91M | $88.40M | $88.25M | $56.25M | -$147.3M |
| Common Stock Issued | -- | $44.31M | $6.01M | -- | $0 | $0 | $0 | -- |
| Share Repurchases | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Financing Cash Flow** | $26.97M | $234.6M | $30.64M | $72.39M | $480K | $0 | $73.12M | $151K |
| **Net Change in Cash** | -$95.22M | $179.4M | -$36.03M | -$16.22M | $44.05M | $35.12M | $91.14M | -$195.2M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -74.7% | -26.6% | -7.3% | -102.2% | -- |
| Return on Assets (ROA) | -53.6% | -24.9% | -6.8% | -65.0% | -46.9% |
| Current Ratio | 9.27x | 21.11x | 51.59x | 9.98x | 0.46x |
| Quick Ratio | 8.66x | 19.95x | 51.28x | 9.41x | 0.38x |
| Debt to Equity | 0.25x | 0.01x | 0.01x | 0.01x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -71.7% | -61.6% | -101.2% | -74.7% | -72.9% | -49.8% | -35.6% | -26.6% |
| Return on Assets (ROA) | -50.6% | -45.9% | -64.2% | -53.6% | -50.8% | -38.3% | -28.4% | -24.9% |
| Current Ratio | 9.13x | 12.56x | 8.60x | 9.27x | 8.50x | 16.65x | 21.11x | 21.11x |
| Quick Ratio | 8.53x | 11.83x | 7.76x | 8.66x | 7.87x | 15.54x | 20.02x | 19.95x |
| Debt to Equity | 0.27x | 0.24x | 0.40x | 0.25x | 0.26x | 0.21x | 0.19x | 0.01x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
